Pfizer
Rare Disease
Medical Affairs

ATTR-CM NEWS-BEAT

Transthyretin amyloid cardiomyopathy (ATTR-CM) - Overcoming Diagnostic Challenges

Dear Physician,

Transthyretin Amyloid cardiomyopathy (ATTR-CM) can manifest with a range of symptoms beyond traditional cardiac presentations. As a specialist in your respective field, your involvement in the early detection and management of ATTR-CM is invaluable.

We believe that raising awareness among professionals like yourself is crucial for timely diagnosis and improved patient outcomes.

Thank you for your attention, and we encourage you to review the newsletter for a deeper understanding of ATTR-CM's diverse clinical presentations and how it may concern you.

For additional educational material (Vlogs, Podcasts, Newsletters, Articles etc.) regarding ATTR-CM please visit our knowledge center

Cardiac Amyloidosis (CA)

Cardiac amyloidosis is an **underdiagnosed**, **progressive** infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. Although there are many different amyloid diseases, 2 types account for over 98% of all cardiac amyloidosis: **immunoglobulin light-chain amyloidosis (AL)** and **Transthyretin Amyloid Cardiomyopathy (ATTR-CM)**[1,6].

ATTR-CM: Background

ATTR-CM may be caused by amyloid deposition derived from either the **effects of age or a point mutation** in the TTR gene coding for the hepatically expressed protein Transthyretin. This leads to the two clinical forms of ATTR, respectively: wild type ATTR (**ATTRwt**, >90% of cases) and Hereditary ATTR (**ATTRm**, <10% of cases)[2,3]. The most prevalent mutation in Israel is **Ser77Tyr**, among families of Jewish Yemenite descent[4,5].

Main Signs and symptoms of ATTR-CM[3,5]

Ocular
Vitreous deposits

Cardiovascular
Signs of **Heart Failure** (mostly **HFpEF**):
Shortness of breath, Edema

Arrythmias
Aortic Stenosis (mostly severe)

Musculoskeletal/orthopedic
Carpal Tunnel Syndrome (Mostly Bilateral)
Ruptured Biceps Tendon
Lumbar Spinal Stenosis

Nervous
Polyneuropathy
Dysautonomia

The Amyloidosis team

Patients with ATTR-CM may initially present to several different healthcare providers due to the spectrum of symptoms[6,9]. This underscores the importance of the involvement of multiple healthcare professionals in raising suspicion, referral, diagnosis, and coordination of care.





Many faces to Amyloidosis: The Hematologist point of view

Watch the highlights of the interview with Prof. Tamar Tadmor, Director of the division of hematology blood bank at Bnei Zion Medical Center

Think Genetics!

Watch the highlights of the interview with Dr. Noa Ruhrman Shachar, Head of cardiogenetic clinic at Raphael Recanati Genetic institute, Beilinson hospital





Things you should know about hATTR mixed phenotype

Watch the highlights of the interview with Dr. Amir Dori, Director of the Neuromascular service at Sheba Medical Center

To learn more about ATTR-CM, Please visit our medical Knowledge center

Thank you for taking time to review this information.
Please reach out if you have any questions or would like to discuss further.

Ronnie Segev, DVM, Medical Affairs Scientist
Ronnie.Segev@pfizer.com
+972-54-5844854

Yoav Shetzer, PhD, Medical Affairs Scientist
yoav.shetzer@pfizer.com
+972-50-7628727

References:

1. Garcia-Pavia, Pablo et al. "Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases." European journal of heart failure vol. 23,4 (2021): 512-526. doi:10.1002/ejhf.2140
2. González-López, Esther et al. "Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope." Revista espanola de cardiologia (English ed.) vol. 70,11 (2017): 991-1004. doi:10.1016/j.rec.2017.05.036
3. McDonagh, Theresa A et al. "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure." European heart journal vol. 42,36 (2021): 3599-3726. doi:10.1093/eurheartj/ehab368
4. Waddington-Cruz, Márcia et al. "Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case-series." Orphanet journal of rare diseases vol. 14,1 34. 8 Feb. 2019, doi:10.1186/s13023-019-1000-1
5. Dori, Amir et al. "Ser77Tyr transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features." Annals of clinical and translational neurology vol. 10,4 (2023): 553-567. doi:10.1002/acn3.51741
6. Maurer, Mathew S et al. "Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis." Circulation vol. 135,14 (2017): 1357-1377. doi:10.1161/CIRCULATIONAHA.116.024438
7. Adams, David et al. "Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression." Orphanet journal of rare diseases vol. 16,1 411. 3 Oct. 2021, doi:10.1186/s13023-021-01960-9
8. Donnelly, Joseph P. and Mazen Hanna. "Cardiac amyloidosis: An update on diagnosis and treatment." Cleveland Clinic journal of medicine vol. 84,12 Suppl 3 (2017): 12-26. doi:10.3949/ccjm.84.s3.02
9. Narotsky, David L et al. "Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging." The Canadian journal of cardiology vol. 32,9 (2016): 1166.e1-1166.e10. doi:10.1016/j.cjca.2016.05.008

EMI-ISR-ROT-0013